EASL2015:基线临床特征的影响及 乙型肝炎病毒突变对疗效 慢性

StephenW

P0550
THE IMPACTS OF BASELINE CLINICAL CHARACTERISTICS AND
HEPATITIS B VIRUS MUTATIONS ON CURATIVE EFFECTS OF
CHRONIC HEPATITIS B TREATED WITH NOVAFERON
W. Daxian1, T. Deming1. 1Department of Infectious Diseases, Xiangya
Hospitalo of Central South University, Changsha, China
E-mail: [email protected]
Background and Aims: Novaferon, which is a new type of IFN, had
approved by State Food and Drug Administration (SFDA) for clinical
trials of new drugs on CHB therapy in 2009. To assess the impacts of
baseline clinical characteristics of patients with chronic hepatitis B
(CHB) and baseline hepatitis B virus (HBV) gene mutations on
curative effects of CHB treated with Novaferon.
Methods: Enrolled patients accepted Novaferon monotherapy for
24 weeks and follow up for 12 weeks. Body mass index (BMI) of
patients, genotype, basal core promoter (BCP) and precore (PC),
reverse transcriptase (RT), S region variants of HBV were
determined prior to Novaferon treatment. Aminotransferase (ALT),
Hepatitis B e antigen (HBeAg), HBVDNA, Hepatitis B surface
antigen (HBsAg) were determined at the beginning of treatment
and 12 weeks after treatment. Then the present study evaluated
the influence of age, gender, genotype, BMI, baseline ALT, HBeAg,
HBV-DNA, HBsAg titer as well as BCP, PC, RT and S region variants
on curative effects of chronic hepatitis B treated with Novaferon.
Results: Results In total of 126 CHB patients who finished the
treatedment and follow-up, 38.9% obtained virological response
and 32.5%, 25.4%, 44.4%, 23.8% obtained HBeAg clearence, HBeAg
seroconversion, biochemical response and combined response
respectively. The baseline DNA level of virological response group
was significantly lower than no-virological response group; the
baseline ALT level were significantly higher in HBeAg clearence
group and HBeAg seroconversion group; female and lower BMI
level was prone to acquired biochemical response. Stepwise logistic
regression analysis showed that PC-P159T (ntC2288A), BCP-N118T
(ntA1726C), BCP-L134L (ntA1775C/G/T) were independent influence
factors for virological response. The frequencies of PC-G182C
(ntG2357T) was significantly higher in groups with HBeAg clearance
group and PC-S64A/T (ntT2003G/A), PC-W28STOP (ntG1896A) was
significantly higher in HBeAg seroconversion groups, combined
response respectively.
Conclusions: Conclusions Novaferon was an effective therapeutic
drug for CHB patients, different response type was influenced by
different clinical characteristics and mutations. Baseline mutations
screening could predict curative effect of Novaferon efficiently and
offered the optimal drugs for CHB patients.

StephenW

P0550
基线临床特征的影响及
乙型肝炎病毒突变对疗效
慢性乙型肝炎治疗的Novaferon
W. Daxian1，T. Deming1。教研室传染病，湘雅
中南大学，长沙，中国的Hospitalo
电子邮件：[email protected]
背景和目的：Novaferon的，这是一种新型干扰素，有
经国家食品药品监督管理局（SFDA）的临床
新的药物对治疗慢性乙型肝炎在2009年试验，以评估的影响
慢性乙型肝炎基线临床特征
（CHB）和基线乙型肝炎病毒（HBV）的基因突变的
CHB的疗效与Novaferon的治疗。
方法：入选患者接受Novaferon的单药治疗
24周和随访12周。身体质量指数（BMI）的
患者中，基因型，基底核心启动子（BCP）和前C（PC），
逆转录酶（RT），S区的HBV变体的人
前Novaferon的处理决定。氨基转移酶（ALT），
乙肝e抗原（HBeAg），HBVDNA，乙肝表面
抗原（HBsAg）均在治疗开始时确定
和治疗后12周。然后本研究评估
年龄的影响，性别，基因型，BMI，基线ALT，大三阳，
HBV-DNA，HBsAg的滴度以及BCP，个人电脑，RT和S区的变体
与Novaferon的治疗慢性乙型肝炎的疗效。
结果：结果共有谁完成的126例慢性乙型肝炎患者
treatedment和随访，38.9％获得病毒学应答
和32.5％，25.4％，44.4％，23.8％获得HBeAg的clearence，大三阳
血清转换，生化反应和响应相结合
分别。病毒学应答组的基线水平的DNA
比无病毒学应答组显著降低;该
基线ALT水平显显著高于大三阳clearence
组和H​​BeAg血清转换组;女性，BMI较低
水平是容易获得的生化反应。逐步逻辑
回归分析表明，PC-P159T（ntC2288A），BCP-N118T
（ntA1726C），BCP-L134L（ntA1775C / G / T）是独立的影响
因素病毒学应答。对PC-G182C频率
（ntG2357T）是显著高于与HBeAg清除组
组和PC-S64A / T（ntT2003G / A），PC-W28STOP（ntG1896A）是
显著高于HBeAg血清转换组，结合
响应分别。
结论：结论的Novaferon是一种有效的治疗
药物CHB患者，不同的反应类型是受
不同的临床特征和基因突变。基线突变
筛查可有效预测Novaferon的疗效和
提供最佳的药物为慢性乙肝患者。